TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16382131

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap and MCV4 vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal Tdap immunization
Number of subjects: 0
Study: 11980744

Group type: EXPERIMENTAL
Intervention: 50 mg pethidine and 25 mg promethazine (premedication group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 100
Study: 9796890

Group type: EXPERIMENTAL
Intervention: Digital imaging
Number of subjects: 4286

Group type: COMPARATOR
Intervention: Optometrist reports
Number of subjects: 4286

Group type: COMPARATOR
Intervention: Ophthalmologist slit‐lamp examination
Number of subjects: 4286
Study: 8547558

Group type: EXPERIMENTAL
Intervention: Group 1: Immediate extubation after reversal of neuromuscular blockade with neostigmine and atropine.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group 2: Elective ventilation for an average duration of 5 hours and 29 minutes post-surgery.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mild hypercarbia induced in patients ventilated post-surgery (PaCO2 51.5 ± 3.7 mmHg).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Restoration of normocarbia (PaCO2 40 ± 2.5 mmHg).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of end-tidal CO2 and frequent blood gas analyses.
Number of subjects: 100
Study: 2226884

Group type: EXPERIMENTAL
Intervention: Haemolite device (salvage autotransfusion)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no cell saver)
Number of subjects: 67
Study: 213837

Group type: EXPERIMENTAL
Intervention: Amitriptyline alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dihydroergotamin (DHE) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline and DHE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dihydroergotamin (DHE) added to amitriptyline
Number of subjects: 100
Study: 30845038

Group type: COMPARATOR
Intervention: Group A: single dose of 2.0 g of TXA orally at 2 hours preoperatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Group B: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3 hours postoperatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Group C: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3 and 9 hours postoperatively
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Group D: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3, 9, and 15 hours postoperatively
Number of subjects: 200
Study: 29924009

Group type: EXPERIMENTAL
Intervention: IMRT + endostar
Number of subjects: 23

Group type: COMPARATOR
Intervention: IMRT + chemotherapy
Number of subjects: 23
Study: 27858874

Group type: EXPERIMENTAL
Intervention: Active rTMS stimulation of right secondary somatosensory cortex (S2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active rTMS stimulation of primary somatosensory cortex (S1) and primary motor cortex (M1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo rTMS treatments
Number of subjects: 16
Study: 24854296

Group type: EXPERIMENTAL
Intervention: 2MD (2‐methylene‐19‐nor‐(20S)‐1α,25‐dihydroxyvitamin D3) at 2.5 ng/bw/day in uremic rats
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 2MD (2‐methylene‐19‐nor‐(20S)‐1α,25‐dihydroxyvitamin D3) after 3 daily oral doses for 4 weeks in postmenopausal women
Number of subjects: 2
Study: 21607928

Group type: EXPERIMENTAL
Intervention: AcrySof IQ ReSTOR SN6AD3 IOL
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AcrySof IQ ReSTOR SN6AD1 IOL
Number of subjects: 36

Group type: COMPARATOR
Intervention: AcrySof IQ SN60WF (Control)
Number of subjects: 36
Study: 21138217

Group type: EXPERIMENTAL
Intervention: Autologous Blood Transfusion (ABT) drain
Number of subjects: 168

Group type: COMPARATOR
Intervention: Suction drain
Number of subjects: 168

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 168
Study: 17427529

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Overall antibiotics
Number of subjects: 225
Study: 15928613

Group type: EXPERIMENTAL
Intervention: Studies with at least one author with a reported conflict of interest
Number of subjects: 179

Group type: COMPARATOR
Intervention: Studies without reported conflicts of interest
Number of subjects: 179
Study: 12216558

Group type: EXPERIMENTAL
Intervention: Low‐shrinking resin composite
Number of subjects: 49

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 49
Study: 9466046

Group type: EXPERIMENTAL
Intervention: Mammography reminder letter
Number of subjects: 202
Study: 8527277

Group type: EXPERIMENTAL
Intervention: Teicoplanin infusion at a dose of 6 mg kg‐1 for 30 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Teicoplanin in CAVH patients
Number of subjects: 11
Study: 2093020

Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg once daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ranitidine, 300 mg b.i.d.
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg o.m.
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.i.d.
Number of subjects: 98
Study: 361056

Group type: EXPERIMENTAL
Intervention: Doxapram hydrochloride (80 mg for females, 95 mg for males)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no doxapram)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxapram hydrochloride
Number of subjects: 100
Study: 30660721

Group type: EXPERIMENTAL
Intervention: Knee arthroplasty (KA)
Number of subjects: 384
Study: 27468823

Group type: EXPERIMENTAL
Intervention: 7.0 mg betamethasone
Number of subjects: 70

Group type: COMPARATOR
Intervention: 8 mg lornoxicam
Number of subjects: 70
Study: 26521817

Group type: EXPERIMENTAL
Intervention: Standard H pylori triple therapy (clarithromycin, metronidazole and lansoprazole)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard otitis media with effusion therapy (amoxicillin and clavulanate)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Amoxicillin and clavulanate (for H pylori stool antigen negative children)
Number of subjects: 134
Study: 24445757

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study: 22972873

Group type: EXPERIMENTAL
Intervention: Single-ring isolation (SRI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Wide antral isolation (WAI)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mitral isthmus line (MIL) ablation
Number of subjects: 220

Group type: COMPARATOR
Intervention: No mitral isthmus line (MIL) ablation
Number of subjects: 220
Study: 19638648

Group type: EXPERIMENTAL
Intervention: Cytological surveillance
Number of subjects: 4201

Group type: EXPERIMENTAL
Intervention: Referral to colposcopy for biopsy and recall if necessary
Number of subjects: 4201

Group type: EXPERIMENTAL
Intervention: Referral to colposcopy with immediate treatment based on colposcopic appearance
Number of subjects: 4201

Group type: COMPARATOR
Intervention: Immediate treatment
Number of subjects: 4201
Study: 17289479

Group type: EXPERIMENTAL
Intervention: Esmolol, 1.5 mg/kg IV
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nicardipine, 0.03 mg/kg IV
Number of subjects: 22
Study: 15561991

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study: 12221343

Group type: EXPERIMENTAL
Intervention: Vibration exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isodynamic lumbar extension exercise
Number of subjects: 60
Study: 9925067

Group type: EXPERIMENTAL
Intervention: 2.5 mg nebulized albuterol
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 7.5 mg nebulized albuterol
Number of subjects: 160
Study: 1653126

Group type: EXPERIMENTAL
Intervention: Commercially available anticalculus dentifrice containing 5.0% soluble pyrophosphate in a 0.243% sodium fluoride silica base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially available anticalculus dentifrice containing 1.3% soluble pyrophosphate and 1.5% of a Gantrez copolymer in a 0.243% sodium fluoride silica base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially available anticalculus dentifrice containing 3.3% soluble pyrophosphate and 1.0% of a Gantrez copolymer in a 0.243% sodium fluoride silica base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice containing 0.243% sodium fluoride in a silica base
Number of subjects: 0
Study: 6604469

Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg diazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg diazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg diazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl only (control group)
Number of subjects: 20
Study: 30633170

Group type: EXPERIMENTAL
Intervention: 0.6 mg·kg rocuronium
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.2 mg·kg cisatracurium
Number of subjects: 120
Study: 28143739

Group type: EXPERIMENTAL
Intervention: 1 × 10^7 cells
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 × 10^7 cells
Number of subjects: 23
Study: 26898856

Group type: EXPERIMENTAL
Intervention: Feedback intervention (letter from Chief Medical Officer and leaflet on antibiotics)
Number of subjects: 1581

Group type: COMPARATOR
Intervention: Control (no communication)
Number of subjects: 1581

Group type: EXPERIMENTAL
Intervention: Patient-focused intervention (patient-focused information promoting reduced use of antibiotics)
Number of subjects: 1581
Study: 24652602

Group type: EXPERIMENTAL
Intervention: Higher genetic ability to process alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low genetic ability to process alcohol
Number of subjects: 0
Study: 21841851

Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) intervention
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sociodemographic variables (parent gender, socioeconomic status, age)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 178
Study: 20842169

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Soy oil (control)
Number of subjects: 66
Study: 18656083

Group type: EXPERIMENTAL
Intervention: PureVision lenses with biguanide-preserved solutions (ReNu MultiPlus, Complete MoisturePlus, AQuify)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opti‐Free Express, RepleniSH, Clear Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Unisol 4 Preservative Free Saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General observation
Number of subjects: 0
Study: 16182828

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: CsA ME
Number of subjects: 205
Study: 15320472

Group type: EXPERIMENTAL
Intervention: Nicorandil infusion during coronary reperfusion therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with Nicorandil
Number of subjects: 0
Study: 10383583

Group type: EXPERIMENTAL
Intervention: Total pelvic exenteration (TPE)
Number of subjects: 50
Study: 9097352

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8385478

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0
Study: 3101154

Group type: EXPERIMENTAL
Intervention: Tidal volume increased (1 L to 1.5 L and 2 L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breathing frequency increased (20, 30, 40 breaths/min)
Number of subjects: 12
Study: 30104117

Group type: EXPERIMENTAL
Intervention: MMR-RIT-Min
Number of subjects: 4516

Group type: EXPERIMENTAL
Intervention: MMR-RIT-Med
Number of subjects: 4516

Group type: COMPARATOR
Intervention: MMR II
Number of subjects: 4516

Group type: COMPARATOR
Intervention: MMR-RIT and MMR II
Number of subjects: 4516
Study: 26264387

Group type: EXPERIMENTAL
Intervention: Fortified milk (1000 mg calcium for pre-M women and 1200 mg calcium for PM women, 96 mg magnesium, 2.4 mg zinc, 15 µg vitamin D, 4 g FOS-inulin per day)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Regular milk (500 mg calcium per day)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 257

Group type: COMPARATOR
Intervention: Regular milk
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Fortified milk and regular milk
Number of subjects: 257
Study: 25153616

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) during gait training sessions (45-min, three times a week)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sensory stimulation during gait training sessions (45-min, three times a week)
Number of subjects: 26
Study: 23053255

Group type: EXPERIMENTAL
Intervention: dinaciclib + aprepitant
Number of subjects: 12

Group type: COMPARATOR
Intervention: dinaciclib alone
Number of subjects: 12
Study: 20360607

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (4 physical therapy sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Physical therapy-supervised rehabilitation program (17 physical therapy sessions)
Number of subjects: 88
Study: 18802161

Group type: EXPERIMENTAL
Intervention: ADAPt‐C collaborative care management
Number of subjects: 472

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 472
Study: 16059590

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 15
Study: 11844944

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study: 10408548

Group type: EXPERIMENTAL
Intervention: Baseline NIHSS score
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: NIHSS scores of 7 to 10
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: NIHSS scores of 11 to 15
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Lacunar stroke (TOAST subtype)
Number of subjects: 1281
Study: 7733040

Group type: EXPERIMENTAL
Intervention: 17.5 micrograms (700 IU) vitamin D/d
Number of subjects: 247

Group type: COMPARATOR
Intervention: 2.5 micrograms (100 IU) vitamin D/d
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 247
Study: 1682593

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm in air)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prostacyclin (24 micrograms/h, intravenous infusion)
Number of subjects: 18
Study: 6759061

Group type: EXPERIMENTAL
Intervention: mianserin (30 to 60 mg daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: nortriptyline (75 to 150 mg daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 86

Group type: COMPARATOR
Intervention: nortriptyline
Number of subjects: 86
Study: 29847892

Group type: EXPERIMENTAL
Intervention: Irsogladine maleate 2 mg, twice daily (39 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (37 patients)
Number of subjects: 100
Study: 29149905

Group type: EXPERIMENTAL
Intervention: Kusamala Program (4-day hospital-based intervention)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (comparison arm)
Number of subjects: 6
Study: 25772138

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 40156

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 40156
Study: 24228748

Group type: EXPERIMENTAL
Intervention: Acupuncture (bilateral needling of acupuncture point ST36 for three days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 21249385

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (Cr) 2 × 5 g/day for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16
Study: 19000234

Group type: EXPERIMENTAL
Intervention: RCTs with a Jadad score of 3 or greater
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Commercially sponsored trials
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Multicentre trials
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Quality of reporting of RCTs
Number of subjects: 332
Study: 16527244

Group type: EXPERIMENTAL
Intervention: Controllable task-lighting system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Controllable task-lighting system with varying dimming speeds
Number of subjects: 10
Study: 14739039

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 and 100 mg/m2 combined)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Docetaxel (all doses)
Number of subjects: 204

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 204
Study: 11596697

Group type: EXPERIMENTAL
Intervention: Three-day regimen (group A): lansoprazole 30 mg p.o. twice daily on day 1, followed by lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily, and azithromycin 500 mg p.o. twice daily on days 2 and 3.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Five-day regimen (group B): lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily for two additional days after the three-day regimen.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for group A and group B.
Number of subjects: 28
Study: 9723660

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 microg once daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 400 microg twice daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral prednisone 7.5 mg once daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral prednisone 15 mg once daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 8045490

Group type: EXPERIMENTAL
Intervention: Adjuvant bolus infusion of Lipiodol containing doxorubicin and mitomycin C
Number of subjects: 50

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 50
Study: 3180298

Group type: EXPERIMENTAL
Intervention: Cefotetan 2g iv every 12 hours
Number of subjects: 165

Group type: COMPARATOR
Intervention: Latamoxef 2g iv every 8 hours
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cefoxitin 2g iv every 6 hours
Number of subjects: 165
Study: 29882264

Group type: EXPERIMENTAL
Intervention: Maternal extreme flexure and hip abduction combined with contralateral side-lying
Number of subjects: 226

Group type: COMPARATOR
Intervention: Contralateral side-lying alone
Number of subjects: 226
Study: 27951511

Group type: EXPERIMENTAL
Intervention: Active prefronto-cerebellar tDCS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham prefronto-cerebellar tDCS
Number of subjects: 42
Study: 25709428

Group type: EXPERIMENTAL
Intervention: Hypoxia group (received hypoxic air, inspired fraction of oxygen 15%-12%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (received normal air, sham hypoxia)
Number of subjects: 16
Study: 23467365

Group type: EXPERIMENTAL
Intervention: Zolpidem (Ambien), a short‐acting GABAA agonist hypnotic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naps with increased spindles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control spindles
Number of subjects: 0
Study: 20962290

Group type: EXPERIMENTAL
Intervention: CSF α-synuclein oligomers levels in PD patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CSF oligomers/total-α-synuclein ratio in PD patients
Number of subjects: 32
Study: 18029294

Group type: EXPERIMENTAL
Intervention: nifedipine GITS
Number of subjects: 7665

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7665
Study: 16075290

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with accurate dose instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with no dose instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with accurate dose instructions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with no dose instructions
Number of subjects: 120
Study: 12525510

Group type: EXPERIMENTAL
Intervention: Paclitaxel (3-hour infusion at 175 mg/m2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flat-fixed dose of paclitaxel (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BSA-based dosing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unbound and total paclitaxel clearance
Number of subjects: 12
Study: 10811496

Group type: EXPERIMENTAL
Intervention: Docetaxel (85 mg/m2) and Cisplatin (75 mg/m2) q3w for up to eight cycles
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TC regimen
Number of subjects: 48
Study: 8785111

Group type: EXPERIMENTAL
Intervention: Laser treatment at 50 mJ, 10 pps for 3 minutes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Laser treatment at 80 mJ, 10 pps for 3 minutes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 11

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 11
Study: 2070108

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units intravenous)
Number of subjects: 11712

Group type: COMPARATOR
Intervention: Control (no fibrinolytic treatment)
Number of subjects: 11712

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 11712

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11712

Group type: EXPERIMENTAL
Intervention: Cerebrovascular events overall
Number of subjects: 11712

Group type: EXPERIMENTAL
Intervention: Cerebrovascular events
Number of subjects: 11712
Study: 7391250

Group type: EXPERIMENTAL
Intervention: High dose alcohol (Incentive Gain)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High dose alcohol (Incentive Loss)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: COMPARATOR
Intervention: No-dose alcohol
Number of subjects: 33
Study: 30846254

Group type: EXPERIMENTAL
Intervention: ACEF score
Number of subjects: 15968

Group type: EXPERIMENTAL
Intervention: ACEF II score
Number of subjects: 15968

Group type: EXPERIMENTAL
Intervention: Recalibrated ACEF model
Number of subjects: 15968